CLINICAL TRIALS

Antisense remains on track to positive clinical trial results

Finfeed Archived Mar 18, 2020

The recent completion of the monitoring phase of Antisense Therapeutics Limited's (ASX: ANP) ATL1102 Phase II Duchenne Muscular Dystrophy (DMD) trial remains on track for the end of March 2020.

Can This ASX Junior Surge Through the Pain Barrier?

Next Investors Archived Mar 02, 2020

Biotech company Regeneus (ASX:RGS) is a regenerative medicine company, and the therapy is a novel stem cell therapy.

Antisense appoints experienced biotech executive

Finfeed Archived Feb 28, 2020

Antisense Therapeutics Limited (ASX:ANP) has appointed Gil Price M.D. as Consultant Medical Director. Dr. Price is a clinical physician trained in internal medicine with a long-standing focus in drug development, adverse drug reactions, drug utilization and regulation.

PharmAust Expands Site Recruitment for Phase II Pet Dog Cancer Trial

Finfeed Archived Dec 11, 2019

PharmAust Ltd (ASX:PAA), a clinical-stage oncology company that’s developing targeted cancer therapeutics for humans and animals, reports that it has expanded site recruitment for its anti-cancer trial in pet dogs with treatment naïve B cell lymphoma.

Ten ‘TechKnows’ to test drive

Finfeed Archived Oct 23, 2019

The TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opportunity to learn more about a range of tech and biotech companies.

Imugene to demonstrate the benefits of combination tumor treatment

Finfeed Archived Oct 21, 2019

Imugene Limited (ASX:IMU) has provided a promising update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology.

Rat's Rant: What's hot, what's not and ... The Canberra Raiders

Finfeed Archived Oct 01, 2019

Change Financial Limited (ASX:CCA) closed up 332% to finish at 54c on $11.2 million stock traded on the back of the successful completion of the build of its innovative payments and card issuing platform marking a key milestone for the company.

A healthy six pack in a hot sector: Part 2

Finfeed Archived Sep 11, 2019

The S&P/ASX 200 Healthcare Sector blitzed the rest of the market, increasing 12.7% against the ASX 200 which interestingly by the start of September was already back in positive territory, up 4.5%.

Imagion MRI applications as a new source of revenue

Finfeed Archived Sep 09, 2019

Imagion Biosystems (ASX:IBX) advised the market of early-stage evidence that the technology could have applications in improving magnetic resonance imaging (MRIs).

Clinical Trials